NASDAQ:NXTM - NxStage Medical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$30.00Today's Range$29.98 - $30.0052-Week Range$23.17 - $30.00Volume2.61 million shsAverage Volume1.51 million shsMarket Capitalization$2.00 billionP/E RatioN/ADividend YieldN/ABeta0.25 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts. Receive NXTM News and Ratings via Email Sign-up to receive the latest news and ratings for NXTM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:NXTM Previous Symbol CUSIP67072V10 CIK1333170 Webhttp://www.nxstage.com/ Phone978-687-4700Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio2.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$393.94 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow103.07 Book Value$3.22 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($0.22) Net Income$-14,470,000.00 Net Margins-1.29% Return on Equity-2.50% Return on Assets-1.60%Miscellaneous EmployeesN/A Outstanding Shares66,680,000Market Cap$2.00 billion Next Earnings DateN/A OptionableOptionable NxStage Medical (NASDAQ:NXTM) Frequently Asked Questions What is NxStage Medical's stock symbol? NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM." How were NxStage Medical's earnings last quarter? NxStage Medical, Inc. (NASDAQ:NXTM) posted its earnings results on Monday, August, 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.00. The medical device company earned $92.20 million during the quarter, compared to analyst estimates of $96.47 million. NxStage Medical had a negative net margin of 1.29% and a negative return on equity of 2.50%. The firm's revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.03) earnings per share. View NxStage Medical's Earnings History. Has NxStage Medical been receiving favorable news coverage? News stories about NXTM stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NxStage Medical earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. Who are some of NxStage Medical's key competitors? Some companies that are related to NxStage Medical include Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), CONMED (CNMD), Natus Medical (BABY), AxoGen (AXGN), Viewray (VRAY), TransMedics Group (TMDX), BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Zynex (ZYXI), Cutera (CUTR), Stereotaxis (STXS) and BioSig Technologies (BSGM). What other stocks do shareholders of NxStage Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other NxStage Medical investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Och-Ziff Capital Management Group (OZM), Gran Tierra Energy (GTE) and ALJ Regional (ALJJ). Who are NxStage Medical's key executives? NxStage Medical's management team includes the folowing people: Mr. Jeffrey H. Burbank, Founder, CEO & Director (Age 56)Mr. Joseph E. Turk Jr., Pres (Age 51)Mr. Matthew W. Towse, Sr. VP, CFO & Treasurer (Age 56)Ms. Winifred L. Swan, Sr. VP, Gen. Counsel & Sec. (Age 55)Dr. Allan J. Collins, Head of Scientific Advisory Board & Chief Medical Officer How do I buy shares of NxStage Medical? Shares of NXTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How big of a company is NxStage Medical? NxStage Medical has a market capitalization of $0.00 and generates $393.94 million in revenue each year. The medical device company earns $-14,470,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. What is NxStage Medical's official website? The official website for NxStage Medical is http://www.nxstage.com/. How can I contact NxStage Medical? NxStage Medical's mailing address is 350 MERRIMACK STREET, LAWRENCE MA, 01843. The medical device company can be reached via phone at 978-687-4700 or via email at [email protected] MarketBeat Community Rating for NxStage Medical (NASDAQ NXTM)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 340 (Vote Outperform)Underperform Votes: 285 (Vote Underperform)Total Votes: 625MarketBeat's community ratings are surveys of what our community members think about NxStage Medical and other stocks. Vote "Outperform" if you believe NXTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Understanding Price to Earnings Ratio (PE) Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.